EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study

Yasuhiro Fujisawa, Shusuke Yoshikawa, Tatsuya Takenouchi, Shoichiro Mori, Jun Asai, Hisashi Uhara, Yuki Ichigosaki, Taku Fujimura, Yoshiyuki Nakamura, Yasuhiro Nakamura, Fumitaka Ohno, Takeshi Fukumoto und 16 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02747-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Yasuhiro Fujisawa und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Ehime University, 454 Shizugawa, Toon, Ehime, 791-0204, Japan. fujisawa.yasuhiro.fp@ehime-u.ac.jp. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan skin cancer society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant melanoma (MM) is a rare but aggressive cutaneous cancer, accounting for only 2% of skin cancers in Japan but nearly half of skin cancer-related deaths. While the global incidence of MM is rising, its epidemiology varies significantly by ethnicity and geographic region. In Japan, melanoma incidence remains lower than in Western countries, with acral lentiginous melanoma (ALM) being the most prevalent subtype. However, comprehensive epidemiological and clinical data remain limited.

Methods

We analyzed data from 7442 Japanese melanoma patients collected between 2005 and 2022 through the Japanese Melanoma Study (JMS). Demographic, clinical, and survival data were evaluated, including subtype distribution, TNM staging, and treatment outcomes.

Results

ALM was the most common subtype (40.8%), followed by superficial spreading melanoma (20.2%). Lymph node metastasis was observed in 28.6% of cases, and distant metastasis in 10.9%. The BRAF mutation rate was 27.2%, with significantly lower frequencies in ALM (8.5%) and mucosal melanoma (4.8%). Among Stage IV patients, those treated with both immune checkpoint inhibitors (ICIs) and BRAF(+ MEK) inhibitors demonstrated significantly improved survival compared to chemotherapy alone ( P < 0.05). Adjuvant BRAF(+ MEK) inhibitor therapy also resulted in superior relapse-free survival compared to those who did not receive adjuvant therapy ( P < 0.005).

Conclusion

This study provides the largest dataset of Japanese melanoma patients to date, highlighting distinct epidemiological and clinical characteristics. Given their lower BRAF mutation rates and the limited efficacy of current ICI treatments, these findings emphasize the urgent need for optimize immunotherapy strategies in Japanese melanoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansJapanFemaleMaleMiddle AgedAgedAdultProto-Oncogene Proteins B-rafAged, 80 and overCutaneous Malignant MelanomaNeoplasm StagingImmune Checkpoint InhibitorsMutationYoung AdultIncidenceEast Asian People

Stichwörter der Autor:innen

Clinical subtypeMalignant melanomaStatisticsSurvival

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Ehime University, 454 Shizugawa, Toon, Ehime, 791-0204, Japan. fujisawa.yasuhiro.fp@ehime-u.ac.jp.
  • Department of Dermatology, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Division of Dermatology, Niigata Cancer Center Hospital, Niigata, Japan.
  • Department of Dermatology, Nagoya University, Nagoya, Japan.
  • Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
  • Department of Dermatology, Sapporo Medical University, Sapporo, Japan.

Förderung

  • Japan skin cancer society

Zitieren

APA

Fujisawa, Y., Yoshikawa, S., Takenouchi, T., Mori, S., Asai, J., Uhara, H., Ichigosaki, Y., Fujimura, T., Nakamura, Y., Nakamura, Y., Ohno, F., Fukumoto, T., Ozawa, T., Namikawa, K., Sugihara, S., Hoashi, T., Shimauchi, T., Sawada, Y., Iwata, H., …, & Okuyama, R. (2025). Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02747-9

Vancouver

Fujisawa Y, Yoshikawa S, Takenouchi T, Mori S, Asai J, Uhara H, et al. Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02747-9

BibTeX
@article{Fujisawa2025,
  author = {Fujisawa, Yasuhiro and Yoshikawa, Shusuke and Takenouchi, Tatsuya and Mori, Shoichiro and Asai, Jun and Uhara, Hisashi and Ichigosaki, Yuki and Fujimura, Taku and Nakamura, Yoshiyuki and Nakamura, Yasuhiro and Ohno, Fumitaka and Fukumoto, Takeshi and Ozawa, Toshiyuki and Namikawa, Kenjiro and Sugihara, Satoru and Hoashi, Toshihiko and Shimauchi, Takatoshi and Sawada, Yu and Iwata, Hiroaki and Maeda, Taku and Miyagawa, Takuya and Shibayama, Yoshitsugu and Hatta, Naohito and Kishi, Akiko and Ishikawa, Masashi and Kawahira, Hisao and Katoh, Norito and Okuyama, Ryuhei},
  title = {Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02747-9}
}
Kostenlos starten →